Gene Therapy Turns Hearing Back On: Regeneron Wins First‑in‑Class FDA Approval for OTOF‑Related Deafness

Regeneron Pharmaceuticals (NASDAQ: REGN ) has won FDA approval for DB‑OTO, a first-in-class gene therapy designed to treat a rare congenital hearing loss caused by mutations in the OTOF gene. The therapy targets infants and young children with profound genetic deafness who currently have limited treatment options beyond cochlear implants.

What Is DB-OTO Gene Therapy?

DB-OTO is an adeno-associated virus (AAV)-based gene therapy that delivers a functional copy of the OTOF gene directly into the inner ear through a one-time intracochlear injection. By restoring otoferlin protein function, the therapy enables inner hair cells to transmit sound signals to the brain—effectively reactivating auditory pathways.

This breakthrough approach has the potential to convert profound hearing loss into functional or even near-normal hearing in treated patients.

Clinical Trial Results (CHORD Study)

The FDA approval was supported by strong data from the Phase 1/2 CHORD trial:

• 11 of 12 children showed clinically meaningful hearing improvement after a single dose
• 3 patients achieved normal or near-normal hearing levels
• 9 patients avoided the threshold for cochlear implant recommendation
• Several children gained the ability to hear soft speech or whispers without assistance
• Hearing improvements were observed within weeks and sustained beyond one year in some cases

These results highlight DB-OTO’s potential as a disease-modifying therapy for genetic hearing loss.

Market Opportunity and Investment Outlook

OTOF-related hearing loss is an ultra-rare condition, with only a few dozen new cases annually in the U.S., but several thousand patients across the U.S. and Europe combined. While the commercial opportunity is limited compared to Regeneron’s blockbuster drugs, DB-OTO represents a major strategic milestone.

Key investor takeaways:

• Validates Regeneron’s gene therapy platform in the inner ear
• Opens expansion opportunities into additional auditory gene therapies
• Strengthens Regeneron’s position in genetic medicine beyond ophthalmology and immunology
• Positions the company in the emerging hearing restoration market

DB-OTO marks a significant advancement in precision medicine and reinforces Regeneron’s long-term growth potential in gene therapy innovation.